ARIMIDEX SUMMARY
ARIMIDEX®
Anastrozole
TABLETS
ARIMIDEX® (anastrozole) tablets for oral administration contain 1 mg of anastrozole, a non-steroidal aromatase inhibitor.
ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
The effectiveness of ARIMIDEX in early breast cancer is based on an analysis of recurrence-free survival in patients treated for a median of 31 months (see CLINICAL PHARMACOLOGY
-- Clinical Studies subsection). Further follow-up of study patients will be required to determine long-term outcomes.
ARIMIDEX is indicated for the first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer.
ARIMIDEX is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX.
|
|
NEWS HIGHLIGHTSMedia Articles Related to Arimidex (Anastrozole)
Quality Of Life Better For Breast Cancer Patients Who Have Fun And Friends
Source: Health News from Medical News Today [2013.05.10]
Breast cancer patients who say they have people with whom they have a good time, or have "positive social interactions" with, are better able to deal with pain and other physical symptoms, according to a new Kaiser Permanente study published in Breast Cancer Research and Treatment. "This study provides research-based evidence that social support helps with physical symptoms," said lead author Candyce H. Kroenke, ScD, MPH, staff scientist with the Kaiser Permanente Division of Research. "Social support mechanisms matter in terms of physical outcomes...
Fun And Friends Help Ease The Pain Of Breast Cancer
Source: Health News from Medical News Today [2013.05.10]
Kaiser Permanente study among the first to examine how social relationships influence quality of life in breast cancer patients Breast cancer patients who say they have people to have a good time, or "positive social interactions," with are better able to deal with pain and other physical symptoms, according to a new Kaiser Permanente study published this week in Breast Cancer Research and Treatment. "This study provides research-based evidence that social support helps with physical symptoms," said lead author Candyce H...
Initiation Of Breast Cancer Treatment Varies By Race; Patient-Doctor Communication Is Key
Source: Health News from Medical News Today [2013.05.10]
Black women with breast cancer were found to be three times more likely than their white counterparts to delay treatment for more than 90 days - a time delay associated with increased deaths from the disease, according to a new study led by researchers at Georgetown Lombardi Comprehensive Cancer Center. But many women chose to forgo treatment altogether, and the study, published online in the May issue of Breast Cancer Research and Treatment, suggests that low satisfaction regarding communication between black women and their doctors is a significant reason why they opt out...
Breast Cancer Oncogenes Muted By MicroRNA Cooperation
Source: Health News from Medical News Today [2013.05.10]
A University of Colorado Cancer Center study recently published in the journal Cell Death & Disease shows that turning up a few microRNAs a little may offer as much anti-breast-cancer activity as turning up one microRNA a lot - and without the unwanted side effects. It's a bit like the classic thought experiment known as the "tumor problem" formulated by Karl Dunker in 1945 and used frequently in the problem-solving literature: Imagine a person suffers from a malignant tumor in the center of her body...
How Breast Cancer Cells Acquire Drug Resistance
Source: Health News from Medical News Today [2013.05.10]
A seven-year quest to understand how breast cancer cells resist treatment with the targeted therapy lapatinib has revealed a previously unknown molecular network that regulates cell death. The discovery provides new avenues to overcome drug resistance, according to researchers at Duke Cancer Institute. "We've revealed multiple new signaling pathways that regulate cell death," said Sally Kornbluth, PhD, vice dean of Basic Science and professor of Pharmacology and Cancer Biology at Duke University School of Medicine...
Published Studies Related to Arimidex (Anastrozole)
Lipid profiles within the SABRE trial of anastrozole with and without
risedronate. [2012]
Lipid profiles in women with early breast cancer receiving anastrozole with or
without risedronate were examined within an international Phase III/IV study to
assess for possible treatment related changes. Postmenopausal women with hormone
receptor-positive breast cancer were assigned to 1 of 3 strata by risk of
fragility fracture...
Weight change associated with anastrozole and tamoxifen treatment in
postmenopausal women with or at high risk of developing breast cancer. [2012]
Weight gain is commonly reported by breast cancer patients on tamoxifen or
aromatase inhibitors. Since weight gain may impact on outcome and compliance we
have prospectively assessed the effects of these agents on weight change in three
randomised trials for the treatment or prevention of breast cancer...
Pharmacokinetic comparison of 2 formulations of anastrozole (1 mg) in healthy
Korean male volunteers: a randomized, single-dose, 2-period, 2-sequence,
crossover study. [2012]
formulations in healthy male adult volunteers... CONCLUSION: The test and reference formulations had similar PK parameters and
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for
premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. [2012]
goserelin for early breast cancer in the neoadjuvant setting... INTERPRETATION: Given its favourable risk-benefit profile, the combination of
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. [2011.06.10]
PURPOSE: Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER)-positive breast cancer. To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase III investigations... CONCLUSION: Neoadjuvant AI treatment markedly improved surgical outcomes. Ki67 and PEPI data demonstrated that the three agents tested are biologically equivalent and therefore likely to have similar adjuvant activities. LumA tumors were more likely to have favorable biomarker characteristics after treatment; however, occasional paradoxical increases in Ki67 (12% of tumors with > 5% increase after therapy) suggest treatment-resistant cells, present in some LumA tumors, can be detected by post-treatment profiling.
Clinical Trials Related to Arimidex (Anastrozole)
Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer [Completed]
The main purpose of this study is to determine the effects (good and bad) Iressa plus
anastrozole has on patients with relapsed ovarian cancer.
Gynecomastia Extension Study [Completed]
The purpose of this study is to look at the effect of anastrozole (ZD1033, Arimidex™) in
reducing gynecomastia in pubertal boys treated with placebo in Trial 1033US/0006 (another
anastrozole study).
Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer [Completed]
The purpose of this study is the initial/followed by 5 year adjuvant therapy with
Anastrozole.
Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer [Active, not recruiting]
The investigators want to know if combining Arimidex and Faslodex with Iressa will be an
effective treatment for breast cancer. They also want to know, using special tests on the
tumor, the changes that occur with the treatment so they can try to improve their treatment
for breast cancer in the future.
Open Label Arimidex in Gynecomastia [Completed]
The purpose of this study is to evaluate the safety, effectiveness, pharmacokinetics and
pharmacodynamics of anastrozole (ARIMIDEX™) in the treatment of boys with gynecomastia.
Reports of Suspected Arimidex (Anastrozole) Side Effects
Arthralgia (123),
Neoplasm Malignant (113),
Malaise (86),
Hot Flush (79),
Breast Cancer (78),
Pain in Extremity (67),
Fall (66),
Drug Dose Omission (63),
Fatigue (58),
Alopecia (56), more >>
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Arimidex has an overall score of 9. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
| | Arimidex review by 45 year old female patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Considerably Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | post breast cancer |
| Dosage & duration: | | 1mg taken once a day for the period of 5 years |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | Considered beneficial for post menapausal women to prevent the recurrance of breast cancer. It is a hormone blocker that stops the production of estrogen. Many breast cancer tumors are estrogen positive and thrive in the presence of estrogen. |
| Side effects: | | I had no side effects but possible side effects are, constipation, headaches, nausea, diahrea, weight gain. |
| Comments: | | One 1mg pill once a day for five years following treatment of breast cancer in post menapausal women. |
|
|
|
Page last updated: 2013-05-10
|
